APCCC 2024 | Assessing the pitfalls of next-generation imaging tools in prostate cancer

Declan Murphy, FRACS, FRCS, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the limitations of next-generation imaging tools like whole body magnetic resonance imaging (MRI) and prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in prostate cancer. PSMA PET/CT has been shown to be the best modality for staging prostate cancer, surpassing whole body MRI. Limitations include variability in tracer efficacy, with PSMA-1007 showing high uptake in benign bone lesions. This interview took place at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.